Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo
出版年份 2015 全文链接
标题
Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo
作者
关键词
-
出版物
CANCER BIOLOGY & THERAPY
Volume 16, Issue 12, Pages 1784-1793
出版商
Informa UK Limited
发表日期
2015-11-04
DOI
10.1080/15384047.2015.1095406
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
- (2017) S. Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Panobinostat: First Global Approval
- (2015) Karly P. Garnock-Jones DRUGS
- Current therapeutic strategies for multiple myeloma
- (2015) Yoshihiro Torimoto et al. International Journal of Clinical Oncology
- Belinostat: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
- (2014) Wenxiu Qi et al. Journal of Hematology & Oncology
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
- (2014) L Zhou et al. LEUKEMIA
- Orphan drug designation for pracinostat, volasertib and alvocidib in AML
- (2014) Prithviraj Bose et al. LEUKEMIA RESEARCH
- Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia
- (2014) J. Timothy Caldwell et al. PEDIATRIC BLOOD & CANCER
- Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe
- (2014) M Cornago et al. Cell Death & Disease
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
- (2013) L. Chaudhuri et al. HAEMATOLOGICA
- Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality
- (2013) A. A. Van Linden et al. MOLECULAR CANCER THERAPEUTICS
- Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
- (2013) Jenny M. Kreahling et al. PLoS One
- Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells
- (2013) Guan Wang et al. PLoS One
- Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
- (2013) Chengzhi Xie et al. PLoS One
- RNAi screening of the kinome with cytarabine in leukemias
- (2012) R. Tibes et al. BLOOD
- Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
- (2012) Laura Carrassa et al. CELL CYCLE
- Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia
- (2012) C C Porter et al. LEUKEMIA
- Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
- (2012) Guan Wang et al. PLoS One
- Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
- (2011) Kurtis D. Davies et al. CANCER BIOLOGY & THERAPY
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway
- (2011) H Hasegawa et al. LEUKEMIA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
- (2011) Xuelian Xu et al. PLoS One
- MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
- (2010) Hiroshi Hirai et al. CANCER BIOLOGY & THERAPY
- Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia
- (2010) C. Xie et al. CLINICAL CANCER RESEARCH
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
- (2010) Paul A Marks EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
- (2010) Jeffrey E Rubnitz et al. LANCET ONCOLOGY
- Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
- (2010) A Quintás-Cardama et al. LEUKEMIA
- Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
- (2010) William Brazelle et al. PLoS One
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
- (2010) Julia M. Wagner et al. Clinical Epigenetics
- RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia
- (2009) H. Edwards et al. BLOOD
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes
- (2009) L Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
- (2008) A. Scuto et al. BLOOD
- A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
- (2008) Peter Gimsing et al. EUROPEAN JOURNAL OF HAEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started